




Combined coverage of harm reduction interventions and rates of primary and recurrent HCV infection in a community-based cohort of people who inject drugs

Nanor Minoyan PhD Candidate Centre de Recherche du CHUM / École de Santé Publique, Université de Montréal <u>Co-authors:</u> Andreea Adelina Artenie, Didier Jutras-Aswad, Elise Roy, Geng Zang, ME Turcotte, Julie Bruneau


Disclosures

• Julie Bruneau receives advisor fees from Gilead Sciences and Merck and a research grant from Gilead Sciences, outside of this current work.



Leclerc et al 2018


Syringe distribution by injection material access centres (Quebec, 2005-2016)



Risk behaviours


- Needle sharing : primary risk factor of HCV infection
 - 20% (past 6m, urban PWID)
- High injection frequency
 - \uparrow Manipulations \rightarrow HCV
 - Cocaine injection: 75% (past 6m, Montreal)

SurvUDI - Leclerc et al 2018



Platt et al 2017

3






- 1. Estimate the rate of HCV infection and its association with NSP/OAT coverage among PWID in Montreal;
- 2. Compare estimates among HCV-naïve and previouslyinfected PWID

Methods

HEPatitis COhort (HEPCO)



Design: Prospective longitudinal open cohort study


Aim: To identify individual and contextual determinants of HCV infection among PWID

Setting: Montreal, QC, Canada

Eligibility: drug injection (within past 6m), age ≥18

Recruitment: Combination of street-level strategies and community program referrals

Procedures: Detailed sociodemographic and behavioural questionnaire administered by trained interviewers, HCV testing (every 6/3 months)




HCV antibody testing for primary HCV incidence among Ab-negative



HCV RNA testing for recurrent HCV incidence among Ab+/RNA-

FOR THIS ANALYSIS:



• Ab+/RNA-negative met clinical definitions of treatment-induced (SVR) or spontaneous viral clearance

Exposure variables: opioid agonist treatment

Self-report: Yes/No + current dose

- Not on treatment
- High dose (≥60 mg/day methadone / ≥16 mg/day suboxone)
- Low dose (<60 mg/day methadone / <16 mg/day suboxone)

Based on clinical guidelines and increasing evidence that OAT is effective provided it relieves withdrawal & craving

Exposure variables: needle-syringe program coverage

CACTUS	PHARMACIES
ANONYME	SHOOTING GALLERY
SPECTRE	SECONDARY DISTR.
DOPAMINE	FRIEND/PARTNER
DANS LA RUE (POPS)	DEALER
RELAIS METHADONE	BOUGHT ON STREET
CLINIC/CLSC	FOUND
OUTREACH WORKER	OTHER


previous 3/6m

100% SAFE SOURCES vs <100% SAFE SOURCES

Consistent with Bruneau et al (2011)

Combined harm reduction coverage

NSP COVERAGE




Outcome variable: time-to-HCV infection

- Primary HCV = Ab+ test among Ab-negative
- Recurrent HCV = RNA+ test among Ab+/RNA- defined as having cleared the virus

Analyses

- Time-to-event methods
- Time-updated Cox regression models
 - Adjusted for age (<30, ≥30), gender (m/f), past-month cocaine injection (y/n)
 - Stratified by Ab-status




Results

Study sample

	GROUPS AT RISK					
	GLOBAL	PRIMARY (Ab-)	RECURRENT (Ab+/RNA-)			
Unique participants	422	238	205			
Person-years of follow-up	1183.5	526.2	657.3			
Median follow-up time	25.2m	21.4m	26.2m			

19



Characteristics of eligible HEPCO participant-visits

	OVERALL
Median age	40.8
Male gender	81.7%
Caucasian	88.6%
Drugs injected, past month:	
Heroin	30.6%
Cocaine	38.2%
Prescription opioids	11.8%
Days injected, past month (median)	6.7

HCV Incidence Rates

GLOBAL 106

Rate:	9.0 cases / 100 py
95% CI*:	(7.4-10.8)

*Assuming a Poisson distribution

Cases:

Associations (aHR) between NSP/OAT coverage and time-to-HCV infection

STRATIFIED ANALYSES = GLOBAL ANALYSIS

Associations (aHR*) between combined harm reduction coverage and time-to-HCV infection

NSP		OAT	
100% safe sources	1.00 (ref)	High	1.00 (ref)
<100% safe		Low	2.90 (1.15-6.53)
sources	0.79 (0.41-1.52)	None	4.26 (1.95-9.31)
No injection	0.34 (0.15-0.76)	No injection	1.04 (0.36-3.05)

*Adjusted for age (<30, \geq 30), gender (m/f), past-month cocaine injection (y/n)

Associations (aHR*) between combined harm reduction coverage and time-to-HCV infection

Full	1.00 (ref)
Partial	3.31 (1.53-7.17)
Minimal	2.43 (0.81-7.25)
No injection	0.95 (0.32-2.78)

*Adjusted for age (<30, \geq 30), gender (m/f), past-month cocaine injection (y/n)

Discussion

- Harm reduction similarly associated with HCV regardless of Ab+/- status
- High-dose OAT coverage is particularly important to reduce drug-related harms
- Low % report full coverage of combined harm reduction
 - 1/3 of partially covered report 100% safe sources + no OAT
 Could indicate a difficulty in accessing OAT
- Consistent with previous North American studies, NSP coverage was not significantly associated with HCV infection
 - HCV efficiently transmitted in a stimulant-injecting population
 - Measurement: 100% safe sources variable not detailed enough to capture coverage / injection

26

Strengths

- Prospective, longitudinal cohort design with long follow-up of community-dwelling participants
- Frequent (tri-monthly) RNA testing

Limitations

- Self-reported coverage
- No genotyping info to distinguish reinfection from reactivation
- Loss-to-follow-up
- Residual confounding

Public health implications

- Given the high rate of HCV recurrence observed and low % reporting full harm reduction coverage, scale-up of strategies (OAT*) may be necessary to curtail ongoing HCV epidemics, even in the DAA era
- NSP material needs to remain responsive to needs of PWID within the context of evolving drug trends
- Within cocaine-injecting settings (where OAT may not be indicated), innovative approaches are needed to address HCV transmission (e.g. SIS), including those targeting upstream social vulnerability and stigma

Acknowledgements

COLLABORATORS

- Julie Bruneau
- Marie-Pierre Sylvestre
- Didier Jutras-Aswad
- Élise Roy
- Adelina Artenie
- Stine Hoj
- Brendan Jacka
- Emmanuel Fortier
- Iuliia Makarenko

HEPCO COHORT

- Rachel Bouchard
- Maryse Beaulieu
- Elyse Boucher
- Serge Côté
- Sira Diarra
- Marie-Lyne Girard
- Marie-Eve Turcotte
- Geng Zang







CRCHUM

Supplementary slides

Associations (aHR) between NSP coverage and time-to-HCV infection

	Global Infection	Primary Infection	Recurrent Infection
100% SAFE SOURCES	1.00 (ref)	1.00 (ref)	1.00 (ref)
< 100% SAFE SOURCES	0.79 (0.41-1.52)	0.84 (0.36-1.96)	0.80 (0.29-2.27)
No injection (past 3/6m)	0.34 (0.15-0.76)	0.37 (0.11-1.26)	0.29 (0.10-0.85)

Associations (aHR) between OAT coverage and time-to-HCV infection

	Primary infection	Recurrent infection	Global infection
HIGH DOSE	1.00 (ref)	1.00 (ref)	1.00 (ref)
LOW DOSE	2.75 (1.15-6.53)	2.72 (0.74-10.02)	2.50 (0.78-8.05)
NOT ON OAT	4.14 (1.90-9.04)	3.54 (1.09-11.53)	4.63 (1.63-13.17)
NO INJECTION	1.01 (0.35-2.96)	1.04 (0.20-5.33)	0.86 (0.21-3.57)

32

	À RISQUE DE V	VHC PRIMAIRE	À RISQUE DE VHC RÉCURRENTE	
			100% SOURCES SÉCURITAIRES	< 100% SOURCES SÉCURITAIRES
TAO ÉLEVÉE	Complete: 1.00 (ref)		Complete 1.00 (ref)	
TAO FAIBLE		n rtial:).92-9.63)		ortial: I.16-9.10)
TAO AUCUNE		Minimal: 1.58 (0.32-7.86)		Minimal: 3.70 (0.82-16.64)

Characteristics	Full coverage N=540 (16.2%) n (%)	Partial coverage N=1772 (53.3%) n (%)	Minimal coverage N=203 (6.1%) n (%)	No injection N=812 (24.4%) n (%)
Age at baseline				
Median (Q1-Q3)	39.9 (32.0-47.7)	39.4 (30.5-46.9)	44.2 (36.7-47.1)	42.5 (34.0-39.3)
Aboriginal, Inuit or Metis Yes	15 (2.8)	95 (5.4)	1 (0.5)	22 (2.7)
Ethnicity Caucasian	491 (90.9)	1525 (86.4)	201 (99.0)	715 (88.3)
Gender				
Male	418 (77.4)	1438 (81.2)	175 (86.2)	686 (84.5)
HIV status				
Positive	11 (2.0)	110 (6.2)	11 (5.4)	50 (6.2)
Housing Unstable ^c	93 (17.3)	468 (26.4)	56 (27.6)	201 (24.8)
Recent incarceration ^d				
Yes	32 (5.9)	148 (8.4)	13 (6.4)	65 (8.0)
Cocaine injection ^a				
Yes	248 (45.9)	903 (51.0)	121 (59.6)	NA
Prescription opioid injection ^a				
Yes	130 (24.1)	706 (39.8)	39 (19.2)	NA
Heroin injection ^a Yes	281 (52.0)	712 (40.2)	24 (11.8)	NA
Cocaine & opioid ^e injection ^a			/>	
Yes	124 (23.0)	416 (23.5)	20 (9.9)	NA
Days injected ^a Median (Q1-Q3)	8.0 (2.0-24.25)	10.0 (2.0-30.0)	2.0 (1.0-8.0)	0 (0.0)
Sources of needle- syringes ^b 100% sofo	540 (100.0)	1620 (91.4)	0 (0.0)	ΝΑ

Reinfection?

ligh-risk studies							
Weir et al 2014	277	4.5 (410.0)	Terminology	0	7 (0)	7	17.07 (8.29-34.82)
Ruzic et al 2013	20	5 (100.0)	-	0	0	0	0.00 (.00-36.99)
Hilsden et al 2013	23	1.8 (35.5)	Risk factors	0	1 (0)	1	28.17 (4.99-143.49)
Edlin et al 2013	15	NR (45.1)	Terminology	0	1 (0)	1	22.17 (3.92-115.43)
Conway et al 2013	70	2.0 (138.6)	Genotyping	0	4 (4)	4	28.86 (11.28-71.85)
Deshaies et al 2013	20	1.6 (31.7)	Genotyping	0	2 (1)	2	63.09 (17.48-203.15)
Grady et al 2012	42	2.0 (110.6)	Sequencing	0	1 (0)	1	9.04 (1.60-49.45)
Manolakopouos et al 2012	61	2.0 (122.0)	Genotyping	0	5 (4)	5	40.98 (17.63-92.36)
Grebely et al 2010	35	2.0 (62.5)	Genotyping and risk factors	0	2 (1)	2	32.00 (8.82-109.38)
Currie et al 2008	9	3.6 (38.0)	Terminology	0	1 (0)	1	26.32 (4.66-134.95)
Backmund et al 2004	18	2.8 (48.8)	Genotyping	0	1 (1)	2	40.98 (11.31-137.65)
Dalgard et al 2002	27	4.9 (118.0)	Genotyping	0	1 (1)	1	8.47 (1.50-46.45)
Marco et al 2013	101	1.4 (148.5)	Genotyping and risk factors	0	6 (5)	6	40.40 (18.65-85.34)
Bate et al 2010	53	3.4 (180.4)	Genotyping	5 (5)	4 (4)	9	49.89 (26.47-92.08)

SIMMONS et al 2016

35

Recent studies among active PWID

- Aspinall2013: 6.4/100py among individuals reporting IDU after txinduced HCV clearance
- Weir2016: For PWID who have been hospitalised for an opiate or injection related cause post SVR (11%), the risk of HCV reinfection was greater [AHR = 12.9, 95% CI 2.2–76.0, p = 0.002] and the reinfection rate was 5.7/100 py (95% CI 1.8–13.3).
- Martinello2017: 7.4 per 100 py (95% CI 4.0, 13.8). Reinfection incidence was significantly higher among participants who reported injection drug use at end of or post-treatment, irrespective of HIV status (15.5 per 100 py, 95% CI 7.8, 31.1).
- Midgard2016: Individuals who had relapsed to IDU after treatment (incidence rate 4.9/100 PY; 95% CI 2.3–8.9).

3327	100% Safe Sources	< 100% Safe Sources	No injection (p6/3m)
High	Full coverage n=540 (16%)		No injection, not on OAT
Low	Partial co n=1894	n=341 (10%)	
None		Minimal coverage n=81 (2%)	Not injecting nor on OAT n=471 (14%)




Figure 4 Seringues remises par les DSP aux CAMI selon les régions, 2015-2016